KLH in Clinical Trials

Clinical trials involving KLH. Details such as study status, design and investigators are available by link to outside sites.

Clinical trial links are intended for informational purposes only, and are not solicitations for any study nor provided for the purposes of giving medical advice. See Terms of Use for this site.

(in order by date)

Entries in KLH-Conjugate (82)

Tuesday
Nov172015

NCT02665364

Study of IFN-K in Systemic Lupus Erythematosus

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Sponsor: Neovacs
Phase 2 

Friday
Oct092015

NCT02579252

24 Months Safety and Efficacy Study of AADvac1 in Patients with Mild Alzheimer's Disease (ADAMANT)

A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Sponsor: Axon Neuroscience SE
Phase 2 

Friday
May222015

NCT02455557

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma

Condition: Glioblastoma
Sponsor: Roswell Park Cancer Institute
Collaborator: National Cancer Institute (NCI) 
Phase 2 

Tuesday
Jan062015

NCT02334865

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Conditions: Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
Sponsor: Roswell Park Cancer Institute
Collaborator: National Cancer Institute (NCI) 
Phase 1

Tuesday
May062014

NCT02132988

Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer

An Open Labeled Phase II Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: Ovarian Cancer
Sponsor: Mackay Memorial Hospital
Collaborator: OBI Pharma, Inc.
Phase II 

Wednesday
Jan012014

NCT02031198

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (FUNDAMANT)

Condition: Alzheimer's Disease
Sponsor: Axon Neuroscience SE
Phase I

Tuesday
Jul232013

NCT01911234

Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis 

Condition: Rheumatoid Arthritis
Sponsor: NeoVacs
Phase: II 

Tuesday
May072013

NCT01850238

Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

Condition: Alzheimer's Disease
Sponsors: Axon Neuroscience
Phase: I 

Thursday
Jan192012

NCT01516307

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
Sponsors: OBI Pharma, Inc.
Phase II

Wednesday
Dec212011

NCT01498328

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)

Conditions: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
Sponsors: Celldex Therapeutics
Phase II